| Symbol | ERGO |
|---|---|
| Name | ENTIA BIOSCIENCES INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 97140 United States OR 21370 SW Langer Farms Parkway Suite 142 |
| Telephone | +1 503-703-4994 |
| Fax | — |
| — | |
| Website | http://entiabio.com |
| Incorporation | US |
| Incorporated On | 2007 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001408299 |
| Description | Entia develops patented, pharmaceutical-grade organic compounds, including one known as ErgoD2. Entia believes that ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. Entias goal is to clinically validate and commercialize ErgoD2 through the prescription Medical Food and OTC Supplement channels. Additional info from OTC: |
SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE
Read moreenGene Announces Board and Leadership Appointments to Support Commercial Readiness
Read moreFDA Grants RMAT Designation for enGenes Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
Read moreSonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results
Read moreReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Read moreReviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
Read moreReviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Read more